Abstract 5205
Background
Our purpose was to study parameters of the cellular immunity in patients with different stages of colorectal cancer with and without circulating tumor cells (CTCs).
Methods
The presence of CTCs and parameters of the cellular immunity were studied in 60 colorectal cancer (CRC) patients: stage II – 20, stage III – 12, stage IV – 28 patients, adenocarcinoma in all cases. Blood levels of CTCs were determined before the treatment using the CellSearch System (Janssen Diagnostics, LLC) with iron microparticles coated with antibodies to epithelial cell adhesion markers EpCAM, CD45 and cytokeratins 8,18,19. Subpopulations of lymphocytes were studied using the FACSCantoII flow cytometer (BD): percentage of T-B-NК-cells, Tregs; activated CD4+ and CD8+ cells, naive T-lymphocytes and memory T cells; expression of CD335, perforin and granzyme B was evaluated in NК cells.
Results
The results revealed a number of differences in immunological parameters in patients with and without CTCs. Stage II CRC with CTCs showed statistically significantly higher content of lymphocytes (19.1±2.7 vs 15.6±1.4%), CD335+ NK cells (44.9±7.6 vs 19.2±4.0%) and the respiratory burst index in granulocytes (97.5±1.6 vs 92.3±1.2%); p < 0.05 in all cases. Stage III CRC with CTCs was characterized by decreased lymphocyte and monocyte levels, while granulocyte content increased. These patients demonstrated elevated levels of CD4+ cells with early and late activation markers: CD38+ and HLA-DR+ by 2 times, CD25+ by 6 times, p < 0.05 in all cases. CTC-positive patients with stage IV CRC, compared to CTC-negative ones, showed lower levels of NK cells (16.6±2.0 vs 28.4±5.5%), CD4+CD69 + (5.1±0.8 vs 8.2±1.0%), and CD8+CD25 + (2.8±0.48 vs 5.5±1.1%; p < 0.05).
Conclusions
CTCs in locally advanced CRC is associated with stimulation of functional parameters of innate immunity and activated Th, while in metastatic CRC - with inhibition of cytotoxic lymphocytes of innate and adaptive immunity, which, apparently, is associated with poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3353 - Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Presenter: Jalid Sehouli
Session: Poster Display session 2
Resources:
Abstract
740 - A real-world analysis of the treatment of advanced ovarian cancer with PARPIs
Presenter: Alejandra Martinez de Pinillos
Session: Poster Display session 2
Resources:
Abstract
5867 - Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Presenter: Robert Morgan
Session: Poster Display session 2
Resources:
Abstract
2966 - Frequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals
Presenter: Jihong Liu
Session: Poster Display session 2
Resources:
Abstract
1687 - BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting
Presenter: Fernanda Milanezi
Session: Poster Display session 2
Resources:
Abstract
3162 - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
Presenter: Changbin Zhu
Session: Poster Display session 2
Resources:
Abstract
5993 - Incidental Early Occult Ovarian Cancer after Risk-Reducing Salpingo-Oophorectomy in BRCA1/2 Mutation Carriers followed in a Community Public Hospital
Presenter: Begona Grana Suarez
Session: Poster Display session 2
Resources:
Abstract
5334 - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status
Presenter: Angela George
Session: Poster Display session 2
Resources:
Abstract
4565 - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?
Presenter: Michele Bartoletti
Session: Poster Display session 2
Resources:
Abstract
3251 - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
Presenter: Fabrice Lecuru
Session: Poster Display session 2
Resources:
Abstract